Fortress Biotech, Inc. (FBIO)
Stock Price:
$2.65 USD
-0.03 (-1.12%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.58 -0.07 (-2.64%) Oct 23, 7:54 PM
Key Info
| Market Cap |
233.22M |
| Revenue (ttm) |
43.28M |
| Net Income (ttm) |
-53.94M |
| Shares Out |
88.01M |
| EPS (ttm) |
-0.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$2.65 |
| Previous Close |
$2.68 |
| Change ($) |
-0.03 |
| Change (%) |
-1.12% |
| Day's Open |
2.68 |
| Day's Range |
2.58 - 2.73 |
| Day's Volume |
928,264 |
| 52-Week Range |
1.04 - 4.78 |
More Stats
| Market Cap |
233.22M |
| Enterprise Value |
144.35M |
| Earnings Date (est) |
Nov 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
88.01M |
| Float |
64.60M |
| EPS (basic) |
-1.29 |
| EPS (diluted) |
-0.87 |
| FCF / Share |
-1.21 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.17M |
| Short Ratio |
1.34 |
| Short % of Float |
3.36% |
| Beta |
2.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
5.39 |
| PB Ratio |
3.86 |
| Revenue |
43.28M |
| Operating Income |
-99.85M |
| Net Income |
-53.94M |
| Free Cash Flow |
-83.10M |
| Net Cash |
88.87M |
| Net Cash / Share |
1.01 |
| Gross Margin |
60.30% |
| Operating Margin |
-230.71% |
| Profit Margin |
-124.60% |
| FCF Margin |
-192.02% |
| ROA |
-25.17% |
| ROE |
-106.89% |
| ROIC |
-33.20% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$8.79*
(231.70% upside)
Low
4.75
Current: $2.65
High
15.00
Target: 8.79
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 36.63 | 26.88 | 17.25 | 16.48 | 0.86 | - | - | - | - | - |
| Revenue Growth | 36.26% | 55.88% | 4.64% | 1809.62% | - | - | - | - | - | - |
| Gross Profit | 26.10 | 20.76 | 13.59 | 15.69 | 0.86 | - | - | - | - | - |
| Operating Income | -111 | -120 | -89.80 | -65.71 | -50.53 | -20.65 | -35.78 | -27.18 | -35.04 | -8.51 |
| Net Income | -39.96 | -84.15 | -66.88 | -55.10 | -48.43 | -20.39 | -37.16 | -27.61 | -36.36 | -9.98 |
| Shares Outstanding | 54.71 | 43.46 | 41.66 | 39.96 | 39.15 | 36.32 | 30.43 | 21.65 | 7.66 | 4.45 |
| Earnings Per Share | -0.73 | -1.94 | -1.61 | -1.38 | -1.24 | -0.56 | -1.22 | -1.27 | -5.51 | -2.24 |
| Operating Cash Flow | -94.96 | -98.85 | -81.31 | -45.81 | -20.38 | -16.33 | -29.65 | -23.19 | -10.95 | -5.68 |
| Capital Expenditures | -2.35 | -7.08 | -0.65 | -6.37 | -0.28 | - | -0.04 | -0.05 | - | -0.01 |
| Free Cash Flow | -97.31 | -106 | -81.95 | -52.18 | -20.66 | -16.33 | -29.69 | -23.25 | -10.95 | -5.69 |
| Cash & Equivalents | 153 | 99.19 | 147 | 108 | 113 | 84.35 | 99.52 | 40.20 | 23.16 | 14.86 |
| Total Debt | 110 | 79.50 | 62.50 | 28.51 | 23.17 | 14.00 | 13.22 | 14.19 | 0.75 | - |
| Net Cash / Debt | 43.28 | 19.68 | 84.46 | 79.71 | 89.59 | 70.34 | 86.30 | 26.01 | 22.41 | 14.86 |
| Assets | 226 | 141 | 246 | 171 | 119 | 89.33 | 101 | 40.99 | 23.38 | 14.94 |
| Liabilities | 154 | 121 | 125 | 87.76 | 34.34 | 18.80 | 19.30 | 18.96 | 4.24 | 1.56 |
| Book Value | 26.22 | 1.85 | 52.57 | 38.50 | 56.85 | 70.52 | 81.28 | 22.03 | 19.13 | -15.90 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Fortress Biotech, Inc. |
| Country |
United States |
| Employees |
93 |
| CEO |
Lindsay Allan Rosenwald |
Stock Information
| Ticker Symbol |
FBIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: FBIO |
Description
Fortress Biotech develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.